Hypoxia-induced Tumor Heterogeneity and Immune Evasion: Clinical Interventions explores how hypoxic stress within the tumor microenvironment drives cancer progression, immune escape, and resistance to therapy. This volume integrates foundational and cutting-edge insights into tumor biology, immunology, and therapeutic innovation. The book is structured into five parts, covering tumor heterogeneity, hypoxia-driven mechanisms, immune evasion, clinical diagnostics, and future directions. It brings together global experts to examine how hypoxia shapes tumor evolution, alters immune responses, and influences treatment outcomes. Topics include metabolic reprogramming, angiogenesis, immune suppression, and hypoxia-targeted therapies, with emphasis on translational relevance. This resource benefits researchers, clinicians, and advanced students by offering a comprehensive, up-to-date synthesis of a rapidly evolving field. It supports deeper understanding of tumor complexity and equips readers with knowledge to inform experimental design, clinical strategies, and therapeutic development in oncology.
Table of Contents
Part I: Introduction and Foundation1. Overview of Tumor Heterogeneity
2. Molecular Basis of Hypoxia
3. Tumor Heterogeneity
4. Environmental Carcinogenesis and Hypoxia
Part II: Hypoxia as a Driver of Tumor Heterogeneity
5. Hypoxia-Induced Clonal Evolution
6. Metabolic Reprogramming by Hypoxia
7. Hypoxia-Driven Angiogenesis
8. Epigenetics and Hypoxia
9. Glycobiology, Vascular Biology and Hypoxia
Part III: Immune Evasion Under Hypoxic Conditions
10. Immune Landscape of Hypoxic Tumors
11. Molecular Mechanisms of Immune Evasion
12. Cross-talk Between Hypoxia and Immunotherapy Resistance
Part IV: Translation and Clinical Perspectives
13. Diagnostic and Imaging
14. Hypoxia-Targeted Therapies
15. Overcoming Immune Evasion Clinically
16. Clinical Strategies to Overcome Immune Evasion
Part V: Future Directions and Challenges
17. Emerging Technologies
18. Personalized Medicine and Precision Oncology
19. Ethical and Regulatory Considerations
Part VI: Conclusions
20. Overall Concluding Remarks
21. References
Authors
Benjamin Bonavida Professor, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, USA.Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).
Salem Chouaib Research Director, Gustave Roussy Cancer Center, Villejuif, France. Dr. Salem Chouaib earned his Ph.D. in Immunology from the University of Pierre and Marie Curie (Paris VI) in 1983. He completed postdoctoral training at Memorial Sloan Kettering Cancer Center before joining INSERM and Institut Gustave Roussy, where he became Research Director and led the Tumor Immunology Lab. His research explores killer cell reactivity and tumor microenvironment dynamics, with a focus on hypoxia's role in immune resistance. A pioneer in cancer immunotherapy, he founded the Thumbay Research Institute for Precision Medicine. Dr. Chouaib has received prestigious awards, including the French League Against Cancer Prize and the Presidential Prize in Biotechnology. He has mentored numerous postdocs, lectures at University Paris-Sud, and has published over 350 scientific works. He also serves as a guest lecturer, journal referee, and scientific advisor globally.
